StockData
Moderna, Inc. logo

Moderna, Inc. (MRNA) stock

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$206.80−8.47 (-3.93%)

Close on Nov 17, 2026Market cap $82.56BP/E –Yield –

Moderna pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Moderna's pe ratio was 28.1× on Oct 31, 2023, against 4.6× a year earlier. Over the last 3 years it ranged from 3.6× to 282.9×, with a median of 10.2×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2023Oct 31, 202328.1×+21.6
2022Dec 30, 20226.5×−9.1
2021Dec 31, 202115.6×–

More Moderna figures

See a number that looks wrong?